|
2024
|
Invention
|
Compositions and methods for modulating pnpla3 expression.
Oligonucleotides and compositions inc... |
|
|
Invention
|
Galnac-conjugated rnai oligonucleotides. Ligand-conjugated oligonucleotide are provided herein th... |
|
|
Invention
|
Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression.
Ol... |
|
2023
|
Invention
|
Stat3 targeting oligonucleotides and uses thereof. The subject matter disclosed herein is directe... |
|
|
Invention
|
Methods for the treatment of nash with advanced fibrosis and/or cirrhosis.
The present invention... |
|
|
Invention
|
Dosage regimen for the treatment of nash.
dsRNAi oligonucleotides can be used in methods for the... |
|
|
Invention
|
Regulation of activity of rnai molecules. Double-stranded oligonucleotides are provided herein th... |
|
|
Invention
|
Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression. Oli... |
|
|
Invention
|
Compositions and methods for inhibiting snca expression.
Oligonucleotides (e.g., RNAi oligonucle... |
|
|
Invention
|
Compositions and methods for inhibiting mapt expression.
Oligonucleotides are provided herein th... |
|
|
Invention
|
Mapt expression. MAPTe.g., MAPT MAPT gene expression. |
|
|
Invention
|
Snca expression. e.g.SNCAe.g. SNCA SNCA gene expression. |
|
|
Invention
|
Methods for synthesis of peracetylgalactosamine-1-pentanoic acid. The disclosure provides methods... |
|
|
Invention
|
Compositions and methods for modulating scap activity.
Oligonucleotides and compositions includi... |
|
|
Invention
|
Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expre... |
|
|
Invention
|
Scap activity. e.g.SCAPSCAPSCAPSCAP-associated conditions, diseases, and/or disorders. |
|
|
Invention
|
Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleo... |
|
|
Invention
|
Combination of stat3 targeting oligonucleotides and pd-l1 inhibitors. The subject matter disclose... |
|
|
Invention
|
Oligonucleotide treatment of hepatitis b patients.
The present invention provides oligonucleotid... |
|
|
Invention
|
Compositions and methods for inhibiting gys2 expression.
This disclosure relates to oligonucleot... |
|
|
Invention
|
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) exp... |
|
2022
|
Invention
|
Reducing beta-catenin expression to potentiate immunotherapy.
Provided herein are methods and co... |
|
|
Invention
|
Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate... |
|
|
Invention
|
Compositions and methods for modulating apoc3 expression.
Oligonucleotides and compositions incl... |
|
|
Invention
|
Compositions and methods for modulating apoc3 expression. Oligonucleotides and compositions inclu... |
|
|
Invention
|
Compositions and methods for modulating apoc3 expression. APOC3APOC3 expression. |
|
|
Invention
|
Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions.
This ... |
|
|
Invention
|
Rnai oligonucleotide conjugates. Lipid-conjugated oligonucleotide are provided herein that inhibi... |
|
|
Invention
|
Lipid conjugation for targeting oligodendrocytes of the central nervous system. Oligonucleotide c... |
|
|
Invention
|
Lipid conjugation for targeting astrocytes of the central nervous system. Oligonucleotide conjuga... |
|
|
Invention
|
Compositions and methods for the treatment of a beta-catenin-associated disease or disorder.
Dis... |
|
|
Invention
|
Compositions and methods for inhibiting melanocortin 2 receptor and cytochrome p450 11b1 expressi... |
|
|
Invention
|
Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna.
... |
|
|
Invention
|
4′-phosphate analogs and oligonucleotides comprising the same. Disclosed herein are oligonucleoti... |
|
|
Invention
|
Compositions comprising reversibly modified oligonucleotides and uses thereof. Disclosed herein a... |
|
|
Invention
|
Lipid conjugation for targeting neurons of the central nervous system.
Oligonucleotide conjugate... |
|
|
Invention
|
Rnai conjugates and uses thereof.
The subject matter disclosed herein is directed to modulating ... |
|
|
Invention
|
Compositions and methods for inhibiting gene expression in the central nervous system.
Oligonucl... |
|
2021
|
Invention
|
Chemical modifications for inhibiting expression of aldh2.
This disclosure relates to chemically... |
|
|
Invention
|
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rn... |
|
|
Invention
|
Compositions and methods for inhibiting αlpha-1 antitrypsin expression. viae.g.e.g., Dicer substr... |
|
|
Invention
|
Selective delivery of oligonucleotides to glial cells.
The present disclosure relates to oligonu... |
|
|
Invention
|
Compositions and methods for inhibiting lpa expression.
Oligonucleotides are provided herein tha... |
|
|
Invention
|
Compositions and methods for inhibiting plp1 expression.
Oligonucleotides are provided herein th... |
|
|
Invention
|
Compositions and methods for the treatment of metabolic syndrome.
Disclosed are methods for trea... |
|
|
Invention
|
Systemic delivery of oligonucleotides.
The disclosure provides oligonucleotide-ligand conjugates... |
|
|
G/S
|
Biologic preparations for use in targeted pharmaceutical therapies for the treatment of rare auto... |
|
|
G/S
|
Biologic preparations for use in targeted pharmaceutical
therapies for the treatment of rare dis... |
|
|
G/S
|
Biological preparations for use in targeted pharmaceutical
therapies for the treatment of rare d... |
|
|
G/S
|
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare ... |
|
|
G/S
|
Oligonucleotide compounds for use in targeted pharmaceutical
therapies for the treatment of rare... |
|
|
Invention
|
Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rn... |
|
|
Invention
|
Compositions and methods for inhibiting angptl3 expression.
Oligonucleotides are provided herein... |
|
|
G/S
|
Custom manufacture of oligonucleotides Biologic preparations for use in targeted pharmaceutical t... |
|
|
Invention
|
4'-o-methylene phosphonate nucleic acids and analogues thereof.
The present invention relates to... |
|
2019
|
G/S
|
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapie... |
|
|
G/S
|
Providing medical and scientific research information in the field of pharmaceuticals and clinica... |
|
2018
|
G/S
|
Pharmaceutical preparations for the treatment of various diseases, namely, rare metabolic, endocr... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic... |
|
2017
|
G/S
|
Biological development platform; biological compounds for use in the targeted pharmaceutical ther... |
|
2016
|
G/S
|
Biologic compounds for use in the delivery of pharmaceutical preparations; biological diagnostics... |
|
2014
|
G/S
|
Scientific research and development; scientific investigations for medical purposes; Providing me... |
